Tecentriq
E46710
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Tecentriq canonical | 3 |
| PD-L1 | 1 |
| atezolizumab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T363289 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tecentriq Context triple: [Genentech, notableProduct, Tecentriq]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Tecentriq Target entity description: Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
cancer immunotherapy
ⓘ
immune checkpoint inhibitor ⓘ monoclonal antibody ⓘ pharmaceutical drug ⓘ |
| administrationSchedule | given every 2 to 4 weeks depending on regimen ⓘ |
| ATCCode | L01FF03 ⓘ |
| belongsToCompanyPortfolio | Roche ⓘ |
| bindsTo | programmed death-ligand 1 ⓘ |
| canBeUsedInCombinationWith |
bevacizumab
ⓘ
chemotherapy ⓘ |
| commonAdverseEffect |
decreased appetite
ⓘ
fatigue ⓘ nausea ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| drugClass |
anti-PD-L1 antibody
ⓘ
checkpoint inhibitor ⓘ |
| firstFDAApprovalYear | 2016 ⓘ |
| hasActiveIngredient | atezolizumab ⓘ |
| hasInternationalNonproprietaryName |
Tecentriq
self-linksurface differs
ⓘ
surface form:
atezolizumab
|
| immuneRelatedAdverseEffect |
colitis
ⓘ
endocrinopathies ⓘ hepatitis ⓘ pneumonitis ⓘ |
| indication |
hepatocellular carcinoma
ⓘ
melanoma ⓘ non-small cell lung cancer ⓘ small cell lung cancer ⓘ triple-negative breast cancer ⓘ urothelial carcinoma ⓘ various solid tumors expressing PD-L1 ⓘ |
| indicationSubtype |
locally advanced or metastatic urothelial carcinoma
ⓘ
metastatic non-small cell lung cancer ⓘ |
| isUsedAs |
first-line cancer therapy in certain indications
ⓘ
second-line cancer therapy in certain indications ⓘ |
| mechanismOfAction |
blocks interaction between PD-L1 and PD-1
ⓘ
enhances T-cell mediated immune response against tumor cells ⓘ |
| molecularType | humanized monoclonal antibody ⓘ |
| regulatoryApproval |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| regulatoryStatus | prescription-only medicine ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
Tecentriq
self-linksurface differs
ⓘ
surface form:
PD-L1
|
| targetSpecies | human ⓘ |
| therapeuticArea |
immuno-oncology
ⓘ
oncology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Tecentriq Description of subject: Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
atezolizumab